FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141840620> ?p ?o ?g. }

• W2141840620 endingPage "2544" @default.
• W2141840620 startingPage "2544" @default.
• W2141840620 abstract "Calcium-channel blockers are metabolized by the cytochrome P450 3A4 (CYP3A4; EC 1.14.13.97) enzyme. Blood concentrations of these drugs may rise to harmful levels when CYP3A4 activity is inhibited. Clarithromycin is an inhibitor of CYP3A4 and azithromycin is not, which makes comparisons between these 2 macrolide antibiotics useful in assessing clinically important drug interactions.To characterize the risk of acute adverse events following coprescription of clarithromycin compared with azithromycin in older adults taking a calcium-channel blocker.Population-based retrospective cohort study in Ontario, Canada, from 2003 through 2012 of older adults (mean age, 76 years) who were newly coprescribed clarithromycin (n = 96,226) or azithromycin (n = 94,083) while taking a calcium-channel blocker (amlodipine, felodipine, nifedipine, diltiazem, or verapamil).Hospitalization with acute kidney injury (primary outcome) and hospitalization with hypotension and all-cause mortality (secondary outcomes examined separately). Outcomes were assessed within 30 days of a new coprescription.There were no differences in measured baseline characteristics between the clarithromycin and azithromycin groups. Amlodipine was the most commonly prescribed calcium-channel blocker (more than 50% of patients). Coprescribing clarithromycin vs azithromycin with a calcium-channel blocker was associated with a higher risk of hospitalization with acute kidney injury (420 patients of 96,226 taking clarithromycin [0.44%] vs 208 patients of 94,083 taking azithromycin [0.22%]; absolute risk increase, 0.22% [95% CI, 0.16%-0.27%]; odds ratio [OR], 1.98 [95% CI, 1.68-2.34]). In a subgroup analysis, the risk was highest with dihydropyridines, particularly nifedipine (OR, 5.33 [95% CI, 3.39-8.38]; absolute risk increase, 0.63% [95% CI, 0.49%-0.78%]). Coprescription with clarithromycin was also associated with a higher risk of hospitalization with hypotension (111 patients of 96,226 taking clarithromycin [0.12%] vs 68 patients of 94,083 taking azithromycin [0.07%]; absolute risk increase, 0.04% [95% CI, 0.02%-0.07%]; OR, 1.60 [95% CI, 1.18-2.16]) and all-cause mortality (984 patients of 96,226 taking clarithromycin [1.02%] vs 555 patients of 94,083 taking azithromycin [0.59%]; absolute risk increase, 0.43% [95% CI, 0.35%-0.51%]; OR, 1.74 [95% CI, 1.57-1.93]).Among older adults taking a calcium-channel blocker, concurrent use of clarithromycin compared with azithromycin was associated with a small but statistically significant greater 30-day risk of hospitalization with acute kidney injury. These findings support current safety warnings regarding concurrent use of CYP3A4 inhibitors and calcium-channel blockers." @default.
• W2141840620 created "2016-06-24" @default.
• W2141840620 creator A5000432740 @default.
• W2141840620 creator A5001731019 @default.
• W2141840620 creator A5022265533 @default.
• W2141840620 creator A5068205401 @default.
• W2141840620 creator A5072465207 @default.
• W2141840620 creator A5081025046 @default.
• W2141840620 creator A5086689815 @default.
• W2141840620 date "2013-12-18" @default.
• W2141840620 modified "2023-10-12" @default.
• W2141840620 title "Calcium-Channel Blocker–Clarithromycin Drug Interactions and Acute Kidney Injury" @default.
• W2141840620 cites W100013426 @default.
• W2141840620 cites W1531474084 @default.
• W2141840620 cites W1972433532 @default.
• W2141840620 cites W1973357685 @default.
• W2141840620 cites W1990125568 @default.
• W2141840620 cites W2000445173 @default.
• W2141840620 cites W2035019909 @default.
• W2141840620 cites W2035380893 @default.
• W2141840620 cites W2040550590 @default.
• W2141840620 cites W2049491523 @default.
• W2141840620 cites W2059796825 @default.
• W2141840620 cites W2061326496 @default.
• W2141840620 cites W2075006590 @default.
• W2141840620 cites W2087759307 @default.
• W2141840620 cites W2088949336 @default.
• W2141840620 cites W2097195964 @default.
• W2141840620 cites W2102424421 @default.
• W2141840620 cites W2102425178 @default.
• W2141840620 cites W2103846010 @default.
• W2141840620 cites W2109641852 @default.
• W2141840620 cites W2110919602 @default.
• W2141840620 cites W2116325340 @default.
• W2141840620 cites W2124467714 @default.
• W2141840620 cites W2131419242 @default.
• W2141840620 cites W2144286150 @default.
• W2141840620 cites W2150093373 @default.
• W2141840620 cites W2151695776 @default.
• W2141840620 cites W2153267334 @default.
• W2141840620 cites W2159234101 @default.
• W2141840620 cites W2167561774 @default.
• W2141840620 cites W2282622959 @default.
• W2141840620 cites W2347121788 @default.
• W2141840620 cites W2599076725 @default.
• W2141840620 doi "https://doi.org/10.1001/jama.2013.282426" @default.
• W2141840620 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24346990" @default.
• W2141840620 hasPublicationYear "2013" @default.
• W2141840620 type Work @default.
• W2141840620 sameAs 2141840620 @default.
• W2141840620 citedByCount "118" @default.
• W2141840620 countsByYear W21418406202013 @default.
• W2141840620 countsByYear W21418406202014 @default.
• W2141840620 countsByYear W21418406202015 @default.
• W2141840620 countsByYear W21418406202016 @default.
• W2141840620 countsByYear W21418406202017 @default.
• W2141840620 countsByYear W21418406202018 @default.
• W2141840620 countsByYear W21418406202019 @default.
• W2141840620 countsByYear W21418406202020 @default.
• W2141840620 countsByYear W21418406202021 @default.
• W2141840620 countsByYear W21418406202022 @default.
• W2141840620 countsByYear W21418406202023 @default.
• W2141840620 crossrefType "journal-article" @default.
• W2141840620 hasAuthorship W2141840620A5000432740 @default.
• W2141840620 hasAuthorship W2141840620A5001731019 @default.
• W2141840620 hasAuthorship W2141840620A5022265533 @default.
• W2141840620 hasAuthorship W2141840620A5068205401 @default.
• W2141840620 hasAuthorship W2141840620A5072465207 @default.
• W2141840620 hasAuthorship W2141840620A5081025046 @default.
• W2141840620 hasAuthorship W2141840620A5086689815 @default.
• W2141840620 hasBestOaLocation W21418406201 @default.
• W2141840620 hasConcept C126322002 @default.
• W2141840620 hasConcept C2776409635 @default.
• W2141840620 hasConcept C2776962512 @default.
• W2141840620 hasConcept C2778907293 @default.
• W2141840620 hasConcept C2779066535 @default.
• W2141840620 hasConcept C2779646130 @default.
• W2141840620 hasConcept C2780356492 @default.
• W2141840620 hasConcept C2780472472 @default.
• W2141840620 hasConcept C2908647359 @default.
• W2141840620 hasConcept C501593827 @default.
• W2141840620 hasConcept C519063684 @default.
• W2141840620 hasConcept C71924100 @default.
• W2141840620 hasConcept C84393581 @default.
• W2141840620 hasConcept C86803240 @default.
• W2141840620 hasConcept C89423630 @default.
• W2141840620 hasConcept C98274493 @default.
• W2141840620 hasConcept C99454951 @default.
• W2141840620 hasConceptScore W2141840620C126322002 @default.
• W2141840620 hasConceptScore W2141840620C2776409635 @default.
• W2141840620 hasConceptScore W2141840620C2776962512 @default.
• W2141840620 hasConceptScore W2141840620C2778907293 @default.
• W2141840620 hasConceptScore W2141840620C2779066535 @default.
• W2141840620 hasConceptScore W2141840620C2779646130 @default.
• W2141840620 hasConceptScore W2141840620C2780356492 @default.
• W2141840620 hasConceptScore W2141840620C2780472472 @default.
• W2141840620 hasConceptScore W2141840620C2908647359 @default.
• W2141840620 hasConceptScore W2141840620C501593827 @default.

• next